ADAP

Adaptimmune Therapeutics
ADAP

Overview Fund Trends Analyst Outlook Journalist POV
Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

43 hedge funds and large institutions have $77.9M invested in Adaptimmune Therapeutics in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

less ownership

Funds ownership: →

less funds holding

Funds holding: →

less capital invested

Capital invested by funds: $ → $

less repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

Holders
43
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$704K
2
+$429K
3
+$185K
4
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$147K
5
HF
HRT Financial
New York
+$53K

Top Sellers

1
-$1.82M
2
-$1.25M
3
-$1.16M
4
Millennium Management
Millennium Management
New York
-$506K
5
Morgan Stanley
Morgan Stanley
New York
-$453K
Name Holding Trade Value Shares
Change 		Change in
Stake
26
$33K
27
$31K
28
$22K
29
$7K
30
$7K
31
$6K
32
$3K
33
$3K
34
$2K
35
$1K
36
$1K
37
$537
38
–
39
–
40
–
41
–
42
–
43
–
44
–
45
–
46
–
47
–
1
2